Wegovy users have five times greater risk of sudden sight loss than Ozempic users, study finds

AI Summary
A recent study published in the British Journal of Ophthalmology found that Wegovy users have a significantly higher risk of sudden vision loss compared to Ozempic users. The study, which analyzed reports submitted to the FDA between 2017 and 2024, revealed that Wegovy patients had a fivefold greater chance of developing non-arteritic anterior ischemic optic neuropathy (NAION), an "eye stroke" causing permanent vision loss. Researchers compared reports of NAION associated with Wegovy, Ozempic, Rybelsus, and Mounjaro. While Wegovy showed a strong association with vision loss, no increased risk was found with Rybelsus or Mounjaro. The higher dosage and faster-acting injection of Wegovy were cited as potential reasons for the increased risk. All drugs contain GLP-1 RAs, which help reduce blood sugar levels, slow digestion and reduce appetite.
Key Entities & Roles
Keywords
Sentiment Analysis
Source Transparency
This article was automatically classified using rule-based analysis.
Topic Connections
Explore how the topics in this article connect to other news stories
Find Similar Articles
AI-PoweredDiscover articles with similar content using semantic similarity analysis.